The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 21, 1999

Filed:

Feb. 05, 1997
Applicant:
Inventors:

Truman R Brown, Laverock, PA (US);

Francis Kappler, Philadelphia, PA (US);

Benjamin Szwergold, Philadelphia, PA (US);

Sundeep Lal, Lansdale, PA (US);

Bangying Su, Philadelphia, PA (US);

Assignee:

Fox Chase Cancer Center, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K / ; A61K / ; A61K / ; A61K / ;
U.S. Cl.
CPC ...
5142388 ; 514 54 ; 514560 ; 514561 ; 514578 ; 514553 ; 514669 ; 514671 ; 514672 ; 514676 ; 514716 ; 514738 ;
Abstract

The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications, as well as methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product.


Find Patent Forward Citations

Loading…